SCHEMBL17544443

SCHEMBL17544443

CNC(=O)c1ccccc1Oc1nc(Nc2cc(OC)ccc2C)ncc1Br

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ULK1 O75385 6/20 0.67
▸ PRKAA2 P54646 1/20 0.67
▸ PRKAA1 Q13131 1/20 0.67
▸ ULK2 Q8IYT8 1/20 0.67
▸ PTK2 Q05397 4/20 0.52
▸ EGFR P00533 3/20 0.51
▸ AXL P30530 1/20 0.47
▸ MERTK Q12866 1/20 0.47
▸ ABL1 P00519 1/20 0.44
▸ PDGFRB P09619 1/20 0.44
▸ BCR P11274 1/20 0.44
▸ PDGFRA P16234 1/20 0.44
▸ PRKCA P17252 1/20 0.44
▸ MAPK3 P27361 1/20 0.44
▸ FGFR1 P11362 1/20 0.43
▸ FGFR2 P21802 1/20 0.43
▸ FGFR4 P22455 1/20 0.43
▸ FGFR3 P22607 1/20 0.43
▸ ZAP70 P43403 1/20 0.43
▸ BRAF P15056 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19654252 0.92 ULK1 (0.55) ULK1PRKAA2PRKAA1ULK2PTK2
SCHEMBL17547499 0.90 ULK1 (0.65) ULK1PRKAA2PRKAA1ULK2PTK2
SCHEMBL17547541 0.86 ULK1 (0.72) ULK1PRKAA2PRKAA1ULK2PTK2
SCHEMBL19654253 0.85 PTK2 (0.61) ULK1PRKAA2PRKAA1ULK2PTK2
SCHEMBL17547457 0.84 ULK1 (0.64) ULK1PRKAA1PTK2EGFRAXL
SCHEMBL19654250 0.83 ULK1 (0.56) ULK1PRKAA2PRKAA1ULK2PTK2
SCHEMBL19654229 0.81 ULK1 (0.89) ULK1PRKAA2PRKAA1ULK2PTK2
SCHEMBL19654241 0.81 ULK1 (0.58) ULK1PRKAA2PRKAA1ULK2PTK2
SCHEMBL17544844 0.80 ULK1 (1.00) ULK1PRKAA2PRKAA1ULK2PTK2
SCHEMBL30562087 0.80 ULK1 (1.00) ULK1PRKAA2PRKAA1ULK2PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230130766-A1 MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS SALK INSTITUTE FOR BIOLOGICAL STUDIES 2023-04-27 — — US disclosed
US-20230130766-A1 MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS SALK INSTITUTE FOR BIOLOGICAL STUDIES 2023-04-27 — — US disclosed
EP-4070795-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME Salk Institute for Biological Studies (US) 2022-10-12 — — EP disclosed
EP-3185868-B1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INST FOR BIOLOGICAL STUDI (US) 2022-04-06 — — EP disclosed
WO-2021163633-A1 MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2021-08-19 — — WO disclosed
US-10774092-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-09-15 — — US disclosed
US-10774092-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-09-15 — — US disclosed
US-10689397-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-06-23 — — US disclosed
US-10689397-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-06-23 — — US disclosed
US-20190284207-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-09-19 — — US disclosed
US-20190152989-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-05-23 — — US disclosed
US-20190152989-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-05-23 — — US disclosed
US-10266549-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2019-04-23 — — US disclosed
US-10266549-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2019-04-23 — — US disclosed
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-11-30 — — US disclosed
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-11-30 — — US disclosed
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-11-30 — — US disclosed
EP-3185868-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME Salk Institute for Biological Studies (US) 2017-07-05 — — EP disclosed
WO-2016033100-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-03-03 — — WO disclosed
WO-2016033100-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-03-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689397-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 ULK1 1/4885PRKAA2 175/4885PRKAA1 143/4885
US-10266549-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 ULK1 1/4885PRKAA2 175/4885PRKAA1 143/4885
US-20230130766-A1 MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS ULK1, ULK2, ULK3 ULK1 1/4885PRKAA2 244/4885PRKAA1 225/4885
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 ULK1 1/4885PRKAA2 181/4885PRKAA1 134/4885
US-20190152989-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 ULK1 1/4885PRKAA2 181/4885PRKAA1 134/4885
US-10774092-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 ULK1 1/4885PRKAA2 175/4885PRKAA1 143/4885
US-20190284207-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 ULK1 1/4885PRKAA2 181/4885PRKAA1 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback